COVID-19 testing

Biocept Reports Second Quarter 2023 Financial Results

Retrieved on: 
Monday, August 14, 2023
Oncology, Health, Health Technology, COVID-19, Clinical Trials, Pharmaceutical, Biotechnology, University, Neuro-Oncology (journal), Marketing, Journal of the National Comprehensive Cancer Network, Clinical trial, G&A, University of California, Doctor of Philosophy, COVID-19 testing, MD, Standard of care, Manuscript, R, Neuro, Research, Northwestern University, Conference, Nursing, Pharmaceutical industry, Video game

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and six months ended June 30, 2023 and provides a business update.

Key Points: 
  • Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and six months ended June 30, 2023 and provides a business update.
  • Net revenues for the second quarter of 2023 were $0.6 million, compared with $5.8 million for the second quarter of 2022, with the decline due to lower RT-PCR COVID-19 testing volume.
  • Cost of revenues for the second quarter of 2023 was $2.6 million, compared with $8.0 million for the second quarter of 2022, with the decrease primarily due to the cessation of COVID-19 testing services and reduced headcount.
  • General and administrative (G&A) expenses for the second quarter of 2023 were $3.5 million, compared with $4.3 million for the second quarter of 2022.

Q&M 1H2023 Core Healthcare Revenue stays resilient as the Group focuses on organic growth plans

Retrieved on: 
Tuesday, August 15, 2023
Well, Acumen, Dental assistant, X-ray, Statutory boards of the Singapore Government, Research, Sepsis, COVID-19 testing, Dentist, EBITDA, COVID-19, Patient, Artificial intelligence, Google Play, Growth, Depreciation, Charitable organization, Pharmaceutical industry, Health insurance, Dentistry, App

- Core Healthcare Business[1] revenue remains resilient and the Group has a healthy net cashflow from operating activities for 1H23 of $14.2 million, providing cash resources for sustainable growth.

Key Points: 
  • - Core Healthcare Business[1] revenue remains resilient and the Group has a healthy net cashflow from operating activities for 1H23 of $14.2 million, providing cash resources for sustainable growth.
  • Dr Ng Chin Siau, Group Chief Executive Officer of Q&M, said, "The continual resilience of Q&M's Core Healthcare Business is well appreciated by investors and reflects the Group's well-established foundations.
  • Further, we will focus on organic growth following significant expansion of our dental clinic network across Singapore and Malaysia in 2022.
  • Beyond Singapore, the Group continues to explore good opportunities to develop a new sustainable growth pillar through organic growth and further expansion of its dental business in Southeast Asia growing private dental healthcare market.

Q&M Free Dental Clinic launched to provide free essential dental treatments for underprivileged individuals and families

Retrieved on: 
Monday, July 10, 2023
Yee, Certificate, Education, Commission, COVID-19, Government, Parliament, COVID-19 testing, Commendation, Dentist, Patient, Nursing, Lunch, Dental care, Charitable organization, Food security, Dental, Dentistry, Tea, Medical device, Health

SINGAPORE, July 10, 2023 - (ACN Newswire) - Q&M Free Dental Clinic Limited, a registered charity under the Commission of Charities, has opened its first Q&M Free Dental Clinic in Chai Chee dedicated to delivering essential dental treatment for underprivileged individuals and families in need.

Key Points: 
  • SINGAPORE, July 10, 2023 - (ACN Newswire) - Q&M Free Dental Clinic Limited, a registered charity under the Commission of Charities, has opened its first Q&M Free Dental Clinic in Chai Chee dedicated to delivering essential dental treatment for underprivileged individuals and families in need.
  • Eligible patients will be initially referred by grassroots organisations within Kembangan-Chai Chee Division and will receive free dental consultation and treatments that are essential to oral health, such as scaling and polishing, fillings, and extractions.
  • Q&M Dental Group led the fundraising efforts to fully equip and set up the free dental clinic, donating S$500,000 to fund the initial costs of renovations and equipment.
  • Dr Mohanarajah s/o S. Senathirajah, Chairman of Q&M Free Dental Clinic Limited, said, "We are really excited to launch the Q&M Free Dental Clinic knowing that we will make a meaningful contribution in the lives of the underprivileged amongst us.

ProPhase Labs Announces Financial Results for the Three Months Ended June 30, 2023

Retrieved on: 
Thursday, August 10, 2023
Nebula, Mayo Clinic, CPT, Marketing, Internet, George Church, Science, Stella, Nebula Genomics, Patient, Whole genome sequencing, Hospital Insurance and Diagnostic Services Act, Three Months, Automation, HRSA, Heart, Therapy, Diagnosis, Hope, Research, Endoscopy, COVID-19 testing, CLIA, Corporation, Medicine, Genetic, Growth, Prophase, System, CDX, IND, Exercise, DNA, Operation Linebacker, Absorption, History, Genetics, Algorithm, FDM, Omicron, Negotiation, Genomics, Cold, Sale, Public expenditure, Genetic counseling, EBITDA, Food, Renewable energy, Pharmaceutical industry, Retail, Cryptocurrency, Tourism, Fine chemical, Vaccine, Microscope, Q2, COVID-19, Bosc

Garden City, NY, Aug. 10, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a next generation biotech, genomics, therapeutics and diagnostics company, today reported its financial and operational results for the three months ended June 30, 2023. The Company announced that despite the slowdown in the Covid-19 testing business, and the significant ramp-up of its multiple growth-oriented subsidiaries, adjusted EBITDA loss for the quarter ended June 30,2023 was $2.2 million in Q2 and that the Company enjoys robust net working capital of $40.2 million as of June 30, 2023.

Key Points: 
  • Company to hold a conference call Thursday, August 10, 2023, at 11:00 AM ET
    Garden City, NY, Aug. 10, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a next generation biotech, genomics, therapeutics and diagnostics company, today reported its financial and operational results for the three months ended June 30, 2023.
  • Revenues grew greater than 100% year-over-year for the six months ended June 30, 2023 as compared to the six months ended June 30, 2022.
  • Three Months Ended June 30, 2023 as compared to the Three Months Ended June 30, 2022.
  • Diagnostic services costs for the three months ended June 30, 2023 were $0.6 million compared to $1.8 million for the three months ended June 30, 2022.

Rhinostics Selected to Exhibit RHINOstic® Automated Swab Platform at Vizient Innovative Technology Exchange

Retrieved on: 
Thursday, August 10, 2023
Medical Supplies, Medical Devices, Health, Hospitals, Health Technology, Other Health, DNA, STI, Massachusetts Innovation & Technology Exchange, COVID-19, Vizient, Inc., The Queen's Award for Enterprise: Innovation (Technology) (2006), Exchange, Multimedia, Doctor of Philosophy, COVID-19 testing, Zenith Contract Services, Hospital, Collection, Laboratory, Robotics, Safety, Medical device

Rhinostics has been selected to exhibit its RHINOstic® Automated Swab platform at the Vizient Innovative Technology Exchange.

Key Points: 
  • Rhinostics has been selected to exhibit its RHINOstic® Automated Swab platform at the Vizient Innovative Technology Exchange.
  • “We are honored to bring our technology platform to Vizient’s Innovative Technology Exchange.
  • “We are pleased to include this technology in the group selected to participate.”
    The annual Innovative Technology Exchange is part of Vizient’s Innovative Technology Program that includes product review of supplier-submitted technologies by member-led councils and task forces.
  • Since 2003, Vizient has reviewed over 1,600 product submissions as part of its Innovative Technology Program.

EQS-News: SYNLAB AG: Continued strong performance in the second quarter of 2023

Retrieved on: 
Wednesday, August 9, 2023
Omicron, FY, Stock dilution, COVID-19, Term loan, D2C, Prognosis, COVID-19 testing, EDT, Sale, EBITDA, FX, CEST, AOP, Growth, LIS, EPS, GBP, Beauty salon, Pharmaceutical industry, Cryptocurrency, AEBITDA, Synnovis

The second quarter saw revenues of €670 million (Q2 2022: €790 million) including only €7 million from COVID-19 testing (Q2 2022: €164 million).

Key Points: 
  • The second quarter saw revenues of €670 million (Q2 2022: €790 million) including only €7 million from COVID-19 testing (Q2 2022: €164 million).
  • Underlying organic growth (excluding COVID-19 testing revenue) accelerated in H1 2023 to 7.1% in comparison to H1 2022 (3.1% normalized for Synnovis).
  • Q2 2023 underlying growth was 4.4% with a volume growth of 3.5% and a price increase of 0.9%.
  • In line with its active portfolio management strategy that aims to improve Group performance, SYNLAB sold its operations in Switzerland in July 2023.

QIAGEN delivers ahead of outlook for Q2 2023 with 9% CER sales growth in non-COVID products and updates 2023 full-year outlook

Retrieved on: 
Tuesday, August 8, 2023
QIAGEN, QGEN, Table, CER, COVID-19, Tax, Original equipment manufacturer, GAAP, Molecular diagnostics, COVID, COVID-19 testing, Huntingdon Life Sciences, Forecasting, Public expenditure, EBITDA, Investment, Plant, Growth, EPS, OEM, PDF, NYSE, QuantiFERON, Pharmaceutical industry

Net sales results of $497 million at constant exchange rates (CER) for Q2 2023 were above the outlook for at least $490 million CER, driven by 9% CER growth in the non-COVID-19 portfolio.

Key Points: 
  • Net sales results of $497 million at constant exchange rates (CER) for Q2 2023 were above the outlook for at least $490 million CER, driven by 9% CER growth in the non-COVID-19 portfolio.
  • Overall sales results for Q2 2023 declined 4% (-4% CER) to $495 million from Q2 2022, a period marked by significant COVID-19 sales.
  • Adjusted diluted earnings per share (EPS) were $0.51, and results of $0.52 CER were above the outlook for at least $0.50 CER.
  • “Our teams at QIAGEN exceeded the outlook we set for both sales and profitability in the second quarter of 2023," said Thierry Bernard, Chief Executive Officer of QIAGEN.

Biodesix Announces Second Quarter 2023 Results and Highlights

Retrieved on: 
Monday, August 7, 2023
Oncology, Medical Devices, Health, Health Technology, Research, Science, Beth Israel Deaconess Medical Center, CMS, Marketing, ISPOR, COVID-19, American Society of Clinical Oncology, Medication, ORACLE, Completeness, NSCLC, COVID, Lung cancer, COVID-19 testing, Test management, Tulane University, ASCO, Medicare, Publication, Patient, International Society, Webcast, Einstein Healthcare Network, Growth, Society, Pharmaceutical industry, Medical imaging, Nursing, Medical device

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced its financial and operating results for the second quarter ended June 30, 2023 and provided a corporate update

Key Points: 
  • Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced its financial and operating results for the second quarter ended June 30, 2023 and provided a corporate update
    “I am very pleased to announce another record-setting quarter from our core lung diagnostics,” said Scott Hutton, President and Chief Executive Officer.
  • All board members, all Section 16 officers, and additional members of the Biodesix leadership team participated in the round raising $27.5 million in equity funding to further support our growth.
  • We also maintained strong cost discipline, with sustainable and improving gross margins to 73% from 65%, and reducing our Operating Expense excluding direct costs and expenses by $2.7 million, all versus first quarter 2023.
  • The Company reaffirms our 2023 financial outlook and expects to generate between $52 million and $55 million in total revenue in 2023.

Fulgent Reports Second Quarter 2023 Financial Results

Retrieved on: 
Friday, August 4, 2023
Genetics, Health, Clinical Trials, Medical Supplies, Therapy, Table, NGS, COVID-19, American Society of Clinical Oncology, Pathology, GAAP, COVID-19 testing, EBITDA, Acquisition, Investment, Cancer, Battle of Saint-Fulgent, Depreciation, Society, Pharmaceutical industry, Bank, Beauty salon

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced financial results for its second quarter ended June 30, 2023.

Key Points: 
  • Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced financial results for its second quarter ended June 30, 2023.
  • Non-GAAP income (loss), non-GAAP income (loss) per share, and adjusted EBITDA income (loss) are described below under “Note Regarding Non-GAAP Financial Measures” and are reconciled to the most directly comparable GAAP financial measure, GAAP income (loss), in the accompanying tables.
  • Our current cash position enables us to continue investing in our business.”
    For the third quarter of 2023, Fulgent expects:
    For the full year 2023, Fulgent now expects:
    Fulgent will host a conference call for the investment community today at 8:30 AM ET (5:30 AM PT) to discuss its second quarter 2023 results.
  • Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information presented in conformity with GAAP, and non-GAAP financial measures as reported by Fulgent may not be comparable to similarly titled metrics reported by other companies.

OPKO Health Reports Second Quarter 2023 Business Highlights and Financial Results

Retrieved on: 
Thursday, August 3, 2023
Intellectual property, Epstein–Barr virus, International, GeneDx, Growth hormone, COVID-19, Health, Research, COVID-19 testing, Sale, Modex, U.S. FDA, OPKO Health, Growth hormone therapy, PIN, Patient, Cancer, United Kingdom, Growth, Merck, Ageing, FDA, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, PCR, Food, Pharmaceutical industry, Video game, EU, Pfizer

MIAMI, Aug. 03, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and six months ended June 30, 2023.

Key Points: 
  • MIAMI, Aug. 03, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and six months ended June 30, 2023.
  • Second quarter business highlights included the following:
    U.S. FDA approved NGENLA™ for pediatric growth hormone deficiency; OPKO earned a $90 million milestone payment from its commercial partner, Pfizer.
  • Operating income was $63.6 million in the second quarter of 2023, compared with $55.4 million in the second quarter of 2022.
  • Operating income for the second quarter of 2023 was $7.0 million compared with an operating loss of $10.7 million for the 2022 quarter.